Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations.

Clin Med Insights Oncol · 2012 · PMC3327515 · PMID 22518088

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

An interim analysis of overall survival also showed a strong trend in favour of pertuzumab arm that awaits confirmation with longer follow-up.

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.